1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 5:Comparison of posttreatment angiographic and clinical outcomes in pediatric NGAVF and vein of Galen malformation
Outcome NGAVF Current Study Posterior Fossa NGAVF Yoshida et al6 Supratentorial NGAVF Weon et al5 VOGM Fullerton et al34 VOGM Lasjaunias et al33 Complete angiographic elimination of arteriovenous shunt 15/25 (60%) 6/14 (43%) 14/35 (40%) 21/27 (78%) 118/216 (55%) Death 2/25 (8%) 2/14 (14%) 2/35 (5.7%) 4/27 (15%) 23/216 (11%) No neurologic deficit or developmental disability 12/25 (48%) 10/14 (71%) 26/35 (74%) 14/27 (52%) 143/216 (66%)